-
Journal of Wildlife Diseases Apr 1974
Topics: Animals; Bird Diseases; Birds; Lice Infestations; Phthiraptera; Stomatitis
PubMed: 4826116
DOI: 10.7589/0090-3558-10.2.135 -
Current Opinion in Oncology Jul 2010Mucositis has long been viewed as an unavoidable consequence of high-dose chemotherapy and/or radiation. Management has been directed to supportive care including oral... (Review)
Review
PURPOSE OF REVIEW
Mucositis has long been viewed as an unavoidable consequence of high-dose chemotherapy and/or radiation. Management has been directed to supportive care including oral pain control, nutritional support, infection treatment and control of diarrhea. Whereas these interventions have been valuable for clinical management, they have not been collectively directed to molecularly targeted prevention and treatment. This review addresses recent advances regarding mucosal injury in cancer patients, with emphasis on symptom clusters, genetically based tissue susceptibility and risk prediction, imaging technology, and computational biology.
RECENT FINDINGS
Modeling of symptom clusters in cancer patients continues to mature. Although integration of mucositis into the paradigm is at an early stage, recent studies suggest that important molecular and clinical insights will emerge in this regard. Initial studies of genetic-based tissue risk are also providing a research basis that may lead to clinical risk prediction models. These advances are in part being engineered via new imaging and computational biology technologies, drawing upon literature in nonmucositis systems. Just as the past decade has been hallmarked by linkage of pathobiology with clinical expression of mucosal toxicity, the next decade promises to identify new molecular interactions and risk prediction models based on novel application of the analytic technologies.
SUMMARY
Recent research has culminated in convergence of molecular pathobiology with models of symptom clusters, genetic-based risk, and imaging and computational biology. The field is poised to further delineate this paradigm, with the goal of development of molecularly targeted drugs and devices for mucositis management.
Topics: Biomedical Research; Computational Biology; Humans; Neoplasms; Pathology, Molecular; Stomatitis
PubMed: 20485169
DOI: 10.1097/CCO.0b013e32833a9fab -
The Journal of the Michigan Dental... Oct 1984
Topics: Diagnosis, Differential; Humans; Recurrence; Stomatitis, Aphthous; Stomatitis, Herpetic
PubMed: 6593469
DOI: No ID Found -
International Journal of Dermatology Jul 2020
Topics: Crohn Disease; Humans; Mouth Mucosa; Organic Chemicals; Stomatitis; Tongue; Tongue Diseases
PubMed: 32415983
DOI: 10.1111/ijd.14932 -
British Journal of Nursing (Mark Allen...Oral mucositis is one of the most common symptomatic dose-limiting complications associated with chemotherapy. However, advice regarding the effectiveness of treatment... (Review)
Review
Oral mucositis is one of the most common symptomatic dose-limiting complications associated with chemotherapy. However, advice regarding the effectiveness of treatment is often conflicting and subjective. Oral dysfunction may affect the quality of life of patients diagnosed with cancer, resulting in taste aversions and associated impaired nutrition, infection, and most importantly treatment delay. This creates a challenge for healthcare professionals to develop clear, research-based mouth-care protocols, with enhanced education and recommendations for both healthcare staff and patients. This article provides an overview of the common oral complications that are often associated with chemotherapy for cancer, supporting healthcare professionals in making prompt and appropriate diagnoses, and identifying the most effective management strategies.
Topics: Antineoplastic Agents; Humans; Pain; Quality of Life; Stomatitis
PubMed: 19057504
DOI: 10.12968/bjon.2008.17.22.31870 -
Journal of Bacteriology Dec 1954
Topics: Animals; Electrons; Microscopy; Microscopy, Electron; Stomatitis; Stomatitis, Aphthous; Vesicular Stomatitis; Viruses
PubMed: 13221548
DOI: 10.1128/jb.68.6.724-726.1954 -
Hematology (Amsterdam, Netherlands) Oct 2002Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic... (Review)
Review
Oral Mucositis (OM) is a frequent cause of severe morbidity in patients receiving chemotherapy and/or radiotherapy. The pathophysiology of OM involves direct cytotoxic effects, local inflammatory responses, and alterations in oral microflora. There are currently no approved agents for the prevention or treatment of OM. In this review we briefly describe current knowledge of the pathophysiology, clinical presentation, and management of OM. We then discuss investigational agents being studied in OM with a particular focus on local antimicrobial agents, hemopoietic growth factors, and cytokines. Measures to reduce the incidence of OM and/or alleviate its clinical sequelae should be incorporated into all chemotherapy or radiotherapy studies.
Topics: Antineoplastic Agents; Disease Management; Hematologic Neoplasms; Humans; Infection Control; Mouth Mucosa; Stomatitis
PubMed: 12850815
DOI: 10.1080/1024533021000037216 -
Oral Surgery, Oral Medicine, Oral... May 2023Our objective was to review the first 20 years of photobiomodulation (PBM) clinical studies for oral mucositis (OM) mitigation. (Review)
Review
OBJECTIVE
Our objective was to review the first 20 years of photobiomodulation (PBM) clinical studies for oral mucositis (OM) mitigation.
STUDY DESIGN
A scoping review screened controlled clinical studies. The PBM devices, protocols, and clinical outcomes were analyzed.
RESULTS
Seventy-five studies met the inclusion criteria. The first study dated from 1992, and the term "PBM" was first published in 2017. Public services, placebo-controlled randomized trials, and patients with head and neck chemoradiation were predominant among included studies. Prophylactic red intraoral laser protocols were mostly used. Comparing the outcomes of all protocols was unfeasible due to missing treatment parameters and nonhomogeneous measurements.
CONCLUSIONS
The main barrier to optimizing clinical protocols of PBM for OM was the lack of standardization in clinical studies. Although PBM use is now globally present in oncology settings and generally marked by good outcomes reported, additional randomized clinical trials with well-described methods are necessary.
Topics: Humans; Low-Level Light Therapy; Stomatitis; Chemoradiotherapy; Light
PubMed: 36870898
DOI: 10.1016/j.oooo.2022.12.010 -
Current Opinion in Otolaryngology &... Apr 2007Oral mucositis is a common regimen-limiting toxicity of radiation therapy and concomitant radiosensitizing chemotherapy for treatment of head and neck cancers. In... (Review)
Review
PURPOSE OF REVIEW
Oral mucositis is a common regimen-limiting toxicity of radiation therapy and concomitant radiosensitizing chemotherapy for treatment of head and neck cancers. In addition to its symptomatic impact, oral mucositis increases the likelihood of unplanned breaks or delays in treatment, reduction in chemotherapy dose, use of feeding tube placement or total parenteral nutrition, the need for an intravenous line, opioid use and hospitalization.
RECENT FINDINGS
Recent research has demonstrated that chemoradiation-induced mucosal injury is the result of a complex series of biological and cellular events that take place predominantly in the submucosa, with the epithelium being the target tissue. From these findings, novel biologically based preventive treatments are being developed, with a number of agents currently in clinical trials. The implications of recent advancements in radiation therapy treatment planning and delivery are also considered.
SUMMARY
Mucositis is a common and serious complication secondary to chemoradiotherapy for head and neck cancer that has a profound effect on morbidity, compliance and treatment outcomes. Currently available interventions are directed at minimizing local radiation exposure and providing symptomatic relief. In the near future, a number of new treatment modalities can be expected to be introduced for reduction of severity and duration of mucositis.
Topics: Chemotherapy, Adjuvant; Head and Neck Neoplasms; Humans; Mouth Mucosa; Oral Ulcer; Radiotherapy, Adjuvant; Stomatitis
PubMed: 17413415
DOI: 10.1097/MOO.0b013e3280523ad6 -
Anticancer Research 2007Oral mucositis is one of the main complications in non-surgical cancer treatments. It represents the major dose-limiting toxicity for some chemotherapeutic agents, for... (Review)
Review
Oral mucositis is one of the main complications in non-surgical cancer treatments. It represents the major dose-limiting toxicity for some chemotherapeutic agents, for radiotherapy of the head and neck region and for some radiochemotherapy combined treatments. Many reviews and clinical studies have been published in order to define the best clinical protocol for prophylaxis or treatment of mucositis, but a consensus has not yet been obtained. This paper represents an updated review of prophylaxis and treatment of antineoplastic-therapy-related mucositis using a MEDLINE search up to May 2006, in which more than 260 clinical studies have been found. They have been divided according to antineoplastic therapy (chemotherapy, radiotherapy, chemo-radiotherapy, high-dose chemotherapy). The prophylactic or therapeutic use of the analysed agents, the number of enrolled patients and the study design (randomized or not) were also specified for most studies. Accurate pre-treatment assessment of oral cavity hygiene, frequent review of symptoms during treatment, use of traditional mouthwashes to obtain mechanical cleaning of the oral cavity and administration of some agents like benzydamine, imidazole antibiotics, tryazolic antimycotics, povidone iodine, keratinocyte growth factor and vitamin E seem to reduce the intensity of mucositis. Physical approaches like cryotherapy, low energy Helium-Neon laser or the use of modern radiotherapy techniques with the exclusion of the oral cavity from radiation fields have been shown to be efficacious in preventing mucositis onset. Nevertheless a consensus protocol of prophylaxis and treatment of oral mucositis has not yet been obtained.
Topics: Humans; Radiation Injuries; Stomatitis
PubMed: 17465250
DOI: No ID Found